Commit 429b02ae authored by 吕祺's avatar 吕祺 ⛹🏽

Update portfolioENPage “portfolioEN”

parent 85b4098c
...@@ -1294,8 +1294,8 @@ portfolioEN: ...@@ -1294,8 +1294,8 @@ portfolioEN:
age-related degenerative diseases and underlying mechanisms, including age-related degenerative diseases and underlying mechanisms, including
regulated cell death, neuroprotective pathways, neuroinflammation, among regulated cell death, neuroprotective pathways, neuroinflammation, among
others. others.
- logo: /static/img/4blogo.png - logo: /static/img/BossZhiping.png
logo2: /static/img/4blogo.png logo2: /static/img/BossZhiping.png
sinceDate: 2019-10-15T12:37:32.377Z sinceDate: 2019-10-15T12:37:32.377Z
nameEN: 4B Technologies nameEN: 4B Technologies
type: 医疗健康 type: 医疗健康
...@@ -1548,20 +1548,4 @@ portfolioEN: ...@@ -1548,20 +1548,4 @@ portfolioEN:
propped by its breakthroughs in auxiliary clinical diagnostics and drug propped by its breakthroughs in auxiliary clinical diagnostics and drug
discovery empowered by AI and omics big data, facilitating precision discovery empowered by AI and omics big data, facilitating precision
medicine. medicine.
- sinceDate: 2019-10-15T12:37:00.000Z
nameEN: 4B Technologies
descriptionEN: 4B Technologies is a biopharmaceutical company with the goal of
developing innovative treatments for nervous system disorders through
internal innovations as well as partnerships around the globe. Our
management team comprises veteran leaders in science and technology,
business, and operations, who have passion, industry experience and track
record in neuroscience drug discovery and development and
commercialization. Innovation, energy, growth, collaboration,and
patient-oriented are our culture and core value. Employees are growing
together with the company to create a long- term vibrant, impactful, and
sustainable future.
logo: /static/img/4blogo.png
logo2: /static/img/4blogo.png
website: http://www.4btechnologies.com/index.aspx
type: 医疗健康
--- ---
Markdown is supported
0% or
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment